iVeena Delivery Systems Announces First Patient Dosed in Phase 1 Study of IVMED-85 in Healthy Adult Volunteers

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems, Inc. (“iVeena”), a clinical-stage ophthalmology company developing novel pharmacologic therapies for refractive eye diseases, today announced that the first participant has been dosed in its Phase 1, first-in-human clinical study of IVMED-85 in healthy adult volunteers. The Phase 1 study is designed to evaluate the safety and tolerability of twice daily dosing of IVMED-85. The randomized, controlled trial is enrolling healthy adult volun